Bio-Techne Corp (TECH): Total Assets
$2.59B
As of 2026-06-30
-0.7%
3-year compound annual growth
+2.7%
5-year compound annual growth
+8.6%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $2.59B | +1.1% | 2026-08-24, Balance as of period end |
| 2025-06-30 | $2.56B | -5.4% | 2026-08-24, Balance as of period end |
| 2024-06-30 | $2.70B | +2.5% | 2025-08-22, Balance as of period end |
| 2023-06-30 | $2.64B | +15.0% | 2024-08-22, Balance as of period end |
| 2022-06-30 | $2.29B | +1.4% | 2023-08-23, Balance as of period end |
| 2021-06-30 | $2.26B | +11.6% | 2022-08-24, Balance as of period end |
| 2020-06-30 | $2.03B | +7.6% | 2021-08-25, Balance as of period end |
| 2019-06-30 | $1.88B | +18.3% | 2020-08-26, Balance as of period end |
| 2018-06-30 | $1.59B | +2.2% | 2019-11-06, Balance as of period end |
| 2017-06-30 | $1.56B | +37.9% | 2018-08-27, Balance as of period end |
| 2016-06-30 | $1.13B | +6.2% | 2017-09-07, Balance as of period end |
| 2015-06-30 | $1.06B | +23.3% | 2016-08-29, Balance as of period end |
| 2014-06-30 | $862.49M | +10.8% | 2016-08-29, Balance as of period end |
| 2013-06-30 | $778.10M | +8.2% | 2015-08-31, Balance as of period end |
| 2012-06-30 | $719.32M | +16.5% | 2014-08-29, Balance as of period end |
| 2011-06-30 | $617.67M | +19.1% | 2013-08-29, Balance as of period end |
| 2010-06-30 | $518.82M | +9.9% | 2012-08-29, Balance as of period end |
| 2009-06-30 | $472.00M | n/a | 2011-08-29, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
| Novavax Inc (NVAX) | 2025-12-31 | $1.18B | -24.6% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $2.53B | +22.4% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $514.16M | +4.8% |
| Moderna, Inc. (MRNA) | 2025-12-31 | $12.34B | -12.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $6.28B | +10.4% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.84B | -3.5% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $4.63B | +24.5% |
Compare TECH, NVAX, HALO, BCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗